Acino’s hydromorphone gets approval in Germany
BASLE - Acino has received the marketing authorization for its hydromorphone product in Germany. The German BfArM (Federal Institute for Drugs and Medical Devices) has completed the review and has approved Acino’s oral capsule formulation of hydromorphone 2mg, 4mg, 8mg, 16mg and 24mg (original prod-uct: Palladon retard / SR from Mundipharma).
- (1888PressRelease) January 19, 2011 - Hydromorphone is a potent opioid analgesic drug used to relieve acute and chronic se-vere pain including pain secondary to cancer. It complements Acino’s offering in the in-dication area pain which includes the marketed products fentanyl (transdermal thera-peutic system), buprenorphine (transdermal therapeutic system) and oxycodone.
Supply contracts have been concluded with two marketing partners and negotiations with two other partners care at an advanced stage. Annual sales are estimated in the mid single-digit million EUR range.
Acino – a focused pharmaceutical company
Acino specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dos-age forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharma-ceutical companies throughout Europe. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration to sourcing, contract manufacturing, packaging and logistics. The Acino Group is headquartered in Basle (Switzerland), currently em-ploys 442 staff and generated annual revenues of about EUR 160 million in 2009. Acino Holding Ltd., the Group’s parent, is listed on the SIX Swiss Exchange (SIX: ACIN).
Contact
Peter Burema
CEO Acino Group
Phone +41 61 338 60 00
info ( @ ) acino-pharma dot com
www.acino-pharma.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam